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Background: Chlamydia trachomatis is an obligate intracellular bacterium characterized by a
biphasic developmental cycle of replication. The organism is recognized as one of the major
causes of sexually transmissible human bacterial infection throughout theworld. Since there have
been no previous studies dealing with chlamydial diagnosis in Palestine, this study was conducted
to determine the prevalence of C. trachomatis infection among women attending gynecology and
infertility clinics.
Methods: Endocervical swabs were collected from 109 women, aged 18—52 years (median 29
years), attending gynecology and infertility clinics in Gaza. These specimens were processed
using molecular (polymerase chain reaction, PCR) and enzyme immunoassay (EIA; IDEIATM PCE
Chlamydia) techniques.
Results: The results obtained show that the overall prevalence rate of C. trachomatiswas 20.2%.
The sensitivity was 73% for the EIA, 86% for the MOMP (major outer membrane protein gene)-
based PCR, and 100% for the plasmid-based PCR. Meanwhile the specificity was 94% for the EIA,
98% for the plasmid-based PCR, and 100% for the MOMP-based PCR. In multivariate analysis, only
cervical discharge was significantly associated with positivity for C. trachomatis (adjusted odds
ratio 5.6, 95% confidence interval 2.0—15.5; p = 0.001).
Conclusions: The study revealed that a significant proportion of Palestinian women expressed
evidence of exposure to C. trachomatis. Women with cervicitis are more likely to have been
previously infected or exposed to Chlamydia infection. Furthermore, PCR proved to be superior
and more efficient in the diagnosis of C. trachomatis than EIA.
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Chlamydia trachomatis is an ubiquitous pathogen worldwide
and causes ocular, urogenital, and respiratory infections in
humans.1 C. trachomatis infection of the lower genital tract
is one of the most prevalent sexually transmitted diseases
(STDs) in the world.2 According to the World Health Organi-
zation (WHO), approximately 89 million new C. trachomatis
infections occur annually worldwide.3 It has been estimated
that there are approximately 4 million new C. trachomatis
infections each year in the USA.4 Among women, the con-
sequences of the disease include pelvic inflammatory dis-
ease, mucopurulent cervicitis, ectopic pregnancy, and
infertility.5 Symptoms of chlamydial infection in women
include: abnormal genital discharge, painful or frequent
urination, burning or itching in the vaginal area, redness,
swelling or soreness of the vulva, and pain in the pelvis during
sexual contact.6
Recently, nucleic acid amplification techniques, such as
the polymerase chain reaction (PCR), with the potential to
offer improved sensitivity for diagnosing C. trachomatis
infections, have become available. These DNA amplification
methods are reported to be more sensitive than cell culture
techniques or conventional antigen detection tests, such as
enzyme immunoassay (EIA).7,8 However, despite the advent
of DNA amplification technology, EIA tests are still widely
used for the diagnosis of C. trachomatis in Palestine.
Althoughmolecular amplification analysis is increasingly used
for confirmation testing, its use as a routine screening test for
C. trachomatis is limited by the high cost for each test
compared with current routine methods. The advent of
improved sensitive immunoassays for detecting chlamydial
lipopolysaccharide (LPS) might offer an opportunity for a
lower cost test, while providing comparable sensitivity to
molecular amplification methods.
The objectives of the present study were to determine the
prevalence of C. trachomatis infection in women attending
gynecology and infertility health centers in Gaza, Palestine,
to identify factors that might be associated with developing
chlamydial infection, and to evaluate the performance of the




The sample size was calculated according to the formula
suggested by Raosoft Inc.,9 with a marginal error of 10%,
confidence level of 95%, and response distribution of 50%.
According to the medical records of Shifa Hospital and the
Basma Infertility Center, the average number of patients in
the previous 6 months was 4500. Therefore, the recom-
mended sample size was 95. However, our study included
134 eligible participants over a period of 6 months from
September 2005 to February 2006. Twenty-five participants
were not enrolled (20 women refused to participate and five
women participated but their endocervical specimens did not
comply with standard collection techniques) and the remain-
ing 109 constituted the study population.
The subjects were married, non-pregnant women, aged
between 18 and 52 years (mean age 30.0  7.5 years,median age 29 years). A questionnaire for the collection
of information on age, level of education, contraceptive
methods, symptoms, and infertility status was completed.
Patients who received antibiotics were excluded. The cases
were selected according to the Centers for Disease Control
and Prevention (CDC) and Wessex Sexual Health Network
guidelines for the management of C. trachomatis genital
infection, where the patients complained of infertility,
cervicitis, pelvic inflammatory disease, deep dyspareunia,
inflamed or friable cervix, contact bleeding, dysuria, and
urethral syndrome.10,11
Specimen collection
The Helsinki Committee, Shifa Hospital, and the Basma
Infertility Center administrations gave permission and ethical
approval for the current study. Following an explanation of
the importance and objectives of the study, each patient
signed a consent form.
Endocervical swab specimens were collected from the 109
participants. For each participant, a specialist gynecologist
collected two Dacron-tipped swabs individually. Swabs for
PCR were placed in phosphate buffered saline (PBS) and
those for EIA testing were placed in special transport medium
(IDEIA Chlamydia collection kit, S600730). The swab speci-
mens were collected randomly and not in an ordered fashion.
Collection was undertaken according to CDC guidelines and
as indicated by the test manufacturer.10
Detection of the lipopolysaccharide epitope of
Chlamydia trachomatis
C. trachomatis antigen was detected by enzyme-linked
immunosorbent assay (IDEIATM PCE Chlamydia; Dako Ltd,
UK). The Chlamydia microplate EIA utilizes a genus-specific
monoclonal antibody for the direct detection of chlamydial
organisms in human urogenital specimens.
Specimen preparation and processing by EIA
Endocervical swabs were placed in a boiling water bath for
15 min before EIA processing. Two hundred microliters of
each heat-treated specimen were added to microwells and
200 ml of each positive and negative control were added to
separate microwells. The negative control was prepared in
triplicate with each batch to find themean absorbance value.
Specimens were incubated for 90 min with shaking at 15—
30 8C, after the addition of 50 ml of conjugates. Specimens
were washed four times with working washing buffer, then
100 ml each of amplifier A and amplifier B were added to each
specimen. After incubation for 30 min with shaking at 15—
30 8C, 100 ml of stop solution was added. The absorbance of
each specimen was read at 490 nm.
Calculation and interpretation of the results
The cut-off value was calculated by adding 0.05 to the mean
of the three negative control absorbance values. A result was
considered positive when the optical density (OD) obtained
was greater than the cut-off value plus 0.015, negative when
the OD obtained was less than the cut-off value minus 0.015,
and equivocal when the OD obtained was equal to the cut-off
value plus orminus 0.015. The cut-off of the results was equal
to 0.23 (0.18 + 0.05), hence positive specimens were defined
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OD490 of <0.215.
Detection of chlamydial DNA by PCR
Swab specimens were collected and stored at 20 8C;
before processing, these were left at room temperature
for at least one hour. Specimens were then well rotated
and transferred to a clean 1.5 ml Eppendorf tube; 200 ml of
PBS were added and the tube closed and centrifuged at
high speed (13 000 rpm) for 30 min. The resulting super-
natant was removed by a micropipette to maintain the
pellet.
DNA extraction
Total DNA was extracted from the pellet by using a QIAmp
DNA Mini Kit with a bacterial DNA extraction protocol. The
pellet was resuspended in 180 ml of buffer ATL (QIAGEN)
with 20 ml of proteinase K and then incubated at 56 8C with
occasional vortexing until the pellet was completely lysed,
which took 30 min. After lysis of the sample, 200 ml of
buffer AL was added to the sample and the mixture was
incubated for 10 min at 70 8C. The mixture was then com-
bined with 200 ml of absolute ethanol and mixed by pulse-
vortexing for 15 s. The mixture was applied to a spin
column, which holds a silica gel membrane, and spun for
1 min at 6000  g. The spin column was washed with 500 ml
of buffer AW2 by centrifugation at 20 000  g for 3 min. The
DNA bound on a membrane was eluted by centrifugation
with 50 ml of buffer AE after incubation for 5 min at room
temperature. The resulting DNA extracts were stored at
20 8C until PCR assessment.
PCR
The extracted DNAs were subjected to PCR with primers
specific for plasmid and the major outer membrane protein
(MOMP) gene. The primers (flanking a region of 364 bp) used to
target the plasmid of C. trachomatis were F, 50-GCAAGATATC-
GAGTATGCGTTGTTAGG-30 and R, 50-TTCATTGTACTCATTAAAC-
GAGCGG-30 (Maxim Biotech Inc., USA). Oligonucleotide
primers (flanking a region of 182 bp) used for MOMP gene
amplification were F, 50-AACTCAAAACCCTCTCATTCTCAA-30
and R, 50-AAACGTTCGTCCCAGGAAGAAGCC-30 (Maxim Biotech
Inc.). The primers (flanking a region of 209 bp) used for the
human b-globin PCR were F, 50-ACACAACTGTGTTCACTAGC-30
and R, 50-GAAACCCAAGAGTCTTCTCT-30 (Operon Biotechnolo-
gies, Germany).12,13 The b-globin primers were used as the
internal control for PCR amplification, for the detection of
any inhibitory specimens. In brief, 5 ml of DNA extracts were
processed in a 25-ml reaction volume using optimized detec-
tion kits for both plasmid and MOMP-based PCRs (Maxim
Biotech Inc.).
Master mix preparation
Two hundred and fifty microliters of each of the pre-mixed
primers were added to each tube of optimized PCR buffer,
aliquoted, and stored at 20 8C. The master mix (20 ml per
PCR assay) and Taq DNA polymerase (0.2 ml per PCR assay)
components were premixed in sufficient quantity for
daily needs, and this working master mix was dispensed
into an individual reaction PCR tube before adding the
specimen or control DNA (5.0 ml per PCR assay). The finalvolume was made up to 25 ml with nuclease free water
when specimen or control cDNA used was less than 5.0 ml.
The positive controls used were both the cDNA included in
the kit and LGV type II DNA control. These showed the
same results.
PCR reaction profiles
Amplifications were carried out in a Mastercycler (Eppen-
dorf). The first cycle, consisting of a 3-min denaturation at
94 8C, was followed by 35 cycles each of 1 min at 94 8C, 1 min
at 56 8C, and 1 min, at 72 8C, with a final extension for 10 min
at 72 8C (for plasmid PCR). The same reaction profile was
used for MOMP DNA, except that the annealing temperature
was set at 59 8C.
Analysis of amplified DNA
Five microliters of amplified specimen were subjected to
electrophoresis in an agarose gel 3%, containing 0.5 mg/ml
ethidium bromide. A band of 364 bp indicated a positive
result for cryptic plasmid, while a band of 182 bp indicated
a positive result for MOMP. In addition, a band of 209 bp
demonstrated that the specimen was positive for the human
b-globin gene.
Interpretation of results
The results were interpreted according to the criteria sug-
gested in previous studies.14,15 Concordance of at least two of
the three methods used (EIA and plasmid- and MOMP-based
PCRs) was used for differentiating positive results from
negative ones. A false-positive for any test was defined in
the case of a positive result for that test and a negative result
for the other two tests. Similarly, a false-negative for a test
was defined in the case of a negative result for that test and a
positive result for the other two tests.
Statistical analysis
Statistical analysis was carried out using the Statistical Pack-
age for Social Sciences (SPSS) version 13 for windows. For
normally distributed data, means and standard deviations
were calculated. Chi-square and Fisher’s exact tests were
applied to assess differences in proportions. The odds ratio
(OR) and its respective 95% confidence interval (CI) were
calculated to assess the magnitude of association between
correlates. Variables found to be significant by univariate
analysis at p values of <0.10 were selected for inclusion in
multivariate modeling. Non-conditional multiple logistic
regression was used to model the association between C.
trachomatis positivity and selected correlates adjusted for
confounding factors identified in the univariate analysis. A p-
value of <0.05 was considered statistically significant. Dis-
cordance between EIA and PCR was assessed by the McNemar
test, while concordance of results was verified by the Kappa
statistic value.
Results
This study is the first study in Palestine that has focused on
the detection of C. trachomatis in endocervical swab speci-
mens. The subjects weremarried, non-pregnant women aged
between 18 and 52 years (mean age 30.0  7.5 years, median







True-positive 16 21 19
True-negative 82 85 87
False-positive 5 2 0
False-negative 6 1a 3
Sensitivity 73 100 86
Specificity 94 98 100
Positive predictive value 76 92 100
Negative predictive value 93 100 98
Efficiency 90 98 97
EIA, enzyme immunoassay; MOMP, major outermembrane protein.
a One false-negative specimen by plasmid PCR was positive by
MOMP PCR. It was included in the true-positive category when
measuring plasmid PCR performance.
Table 1 Comparison between the plasmid- and MOMP-






Plasmid PCR 0.79 0.6
Positive 15 8
Negative 6 80
MOMP PCR 0.79 0.57
Positive 13 6
Negative 8 82
EIA, enzyme immunoassay; MOMP, major outer membrane protein.
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under 24 years of age, 50% were under 29, and 75% were
under 36.
Correlation between the EIA and plasmid- and
MOMP-based PCRs
The plasmid PCR detected 23 positive specimens. It
detected 15 specimens that were positive by EIA
(Table 1); the remaining eight positive specimens were
negative by EIA. Six specimens that were positive by EIA
were identified as negative by plasmid PCR. Hence, a total
of 14 discrepant results was found. There were also 14
discrepant results between the EIA and the MOMP-based
PCR assay. The degree of agreement is based on interpre-
tation of values of the Kappa statistic as described pre-
viously in the literature, in which 0.41 < k < 0.60 is
‘moderate’ agreement. Statistical analysis by Kappa test
revealed moderate agreement between the EIA and the
plasmid PCR (k = 0.6) and between the EIA and the MOMP
PCR (k = 0.57). No statistically significant differences were
shown by McNemar test ( p = 0.79) (Table 1).
MOMP-PCR results
Nineteen specimens were found to be positive by the MOMP
PCR; hence the prevalence by MOMP was 17.4%. There
were six discrepant specimens between the plasmid and
MOMP PCRs; of these six, one specimen was positive by
MOMP PCR and negative by plasmid PCR. The remaining fiveFigure 1 (a) PCR amplification product for cryptic plasmid. Lane 1:m
negative control; lanes 4, 5, 8: positive specimen PCR products (364
product for cryptic plasmid, with internal control. Lane 1: molecular
control; lanes 4, 5, 6, 9: positive specimen PCR products (364 bp); lane
all specimens (209 bp).specimens were negative by MOMP PCR and positive by
plasmid PCR.
Interpretation of the assays in accordance with
the criteria
According to the criteria described previously, the results of
EIA, plasmid-based PCR, and MOMP-based PCR were analyzed
and are summarized in Table 2. By applying the criteria, there
were 22 truly infected women, giving a chlamydial infection
prevalence rate of 20.2% (22/109).
Characteristics and factors associated with
developing chlamydial infection
The prominent symptoms and signs correlatedwith chlamydial
infection were purulent cervical discharge, contact bleeding,
and infertility as determined by univariate logistic regression
(Table 3). However, inmultivariate logistic regression analysis,
cervicitis was the only independent factor significantly asso-
ciated with chlamydial infection (Table 4). Although a higher
rate of chlamydial infection was found in secondary infertility
(33.3%), this was not statistically significant (Table 5).olecular weight ladder (100 bp); lane 2: positive control; lane 3:
bp); lanes 6, 7, 9, 10: negative specimens. (b) PCR amplification
weight ladder (100 bp); lane 2: positive control; lane 3: negative
s 7, 8: negative specimens. The internal control was detected for
Table 3 Prevalence of Chlamydia trachomatis and risk factors among participants.
Characteristics No. tested C. trachomatis positive % p-Value Crude OR 95% CI
Cervicitis
Yes 34 14 41.2 0.0002 5.9 2.15—15.97
No 75 8 10.7
Contact bleeding
Yes 13 6 46.2 0.023 a 4.3 1.27—14.45
No 96 16 16.7
Infertility
Yes 49 14 28.6 0.049 2.6 0.99—6.85
No 60 8 13.3
Low abdominal pain
Yes 25 8 32 0.094 2.35 0.85—6.51
No 84 14 16.7
Low back pain
Yes 27 6 22.2 0.76 1.2 0.41—3.40
No 82 16 19.5
Dysuria
Yes 21 7 33.3 0.13a 2.4 0.84—7.05
No 88 15 15
Pruritis
Yes 24 6 25 0.57a 1.4 0.49—4.2
No 85 16 18.8
Dyspareunia
Yes 28 9 32.1 0.067 2.5 0.92—6.7
No 81 13 16.0
Menstruation
Irregular 22 7 31.8 0.14a 2.24 0.78—6.44
Regular 87 15 17.2
Age group (years)
18—24 30 3 10 0.103 0.35 0.096—1.29
25—31 38 9 23.7 0.5 1.38 0.53—3.62
32—38 25 7 28 0.27 1.79 0.63—5.0
39—45 13 2 15.4 0.65 0.69 0.14—3.37
Education level
Elementary 21 7 33.3 0.128a 2.43 0.84—7.051
Preparatory 19 4 21.1 1.0a 1.067 0.32—3.60
Secondary 45 9 20 0.97 0.98 0.38—2.54
Higher education 24 2 8.3 0.15a 0.29 0.064—1.37
Residence
Rural 31 7 22.6 0.69 1.22 0.44—3.37
Urban 78 15 19.2
OR, odds ratio; CI, confidence interval.
a Fisher’s exact test.
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The amplified products for both plasmid- and MOMP-based
PCR assays are shown in Figures 1 and 2. Figure 1(a) shows the
amplified products for the plasmid-based PCR assay (364 bp).
Figure 1(b) shows the amplified products for the plasmid-
based PCR assay with internal control for the b-globin gene
(209 bp). Figure 2 shows the amplified products for the
MOMP-based PCR assay (182 bp).Discussion
C. trachomatis is one of the most common causes of STDs. It
is the most common cause of cervicitis and urethritis, and
their sequelae (pelvic inflammatory disease, chronic pelvic
pain, tubal factor infertility, and reactive arthritis).16 Chla-
mydial infections are primarily an issue of women’s health-
care since the manifestations and consequences are more
damaging to the reproductive health in women than in
Table 5 Chlamydial infection in relation to type of infertility.
Type of infertility Chlamydial infection p-Value
True positive (%) True negative (%)
Primary 8 (25.8) 23 (74.2) 0.36
Secondary 6 (33.3) 12 (66.7) 0.13a
None 8 (13.3) 52 (86.7) -
Total 22 (20.2) 87 (79.8)
a Fisher’s exact test, 2-tailed.
Table 4 Multivariate logistic regression analysis of factors associated with Chlamydia trachomatis infection.
Characteristic Crude OR (95% CI) Adjusted OR (95% CI) p-Value
Cervicitis 5.9 (2.15—15.97) 5.6 (2.0—15.5) 0.001
Contact bleeding 4.3 (1.27—14.45) 1.28 (0.29—5.69) 0.74
Infertility 2.6 (0.99—6.85) 2.39 (0.85—6.7) 0.079
OR, odds ratio; CI, confidence interval.
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ally asymptomatic but may subsequently cause consider-
able long-term morbidity. Consequently, accurate diagnosis
of C. trachomatis infection requires the use of specific
laboratory techniques.
This study was performed to determine the prevalence of
C. trachomatis infection amongwomen attending gynecology
and infertility centers in Gaza. This is the first study using EIA
and PCR assays for the detection of C. trachomatis in endo-
cervical swab specimens in Palestine. The overall prevalence
of C. trachomatis in the study population was 20.2%. These
results show that the prevalence rate of C. trachomatis is
higher in Gaza than that reported in some neighboring coun-
tries.18—20 However, other studies from neighboring and
developing countries have shown higher prevalence rates
than ours.6,21,22
The wide variation of Chlamydia prevalence in different
studies could be due to several factors, such as study popula-
tion (i.e., selection of high-risk groups), hygiene levels,
socioeconomic status, and different techniques employed.
Correlation between the EIA/plasmid-based PCR and the
EIA/MOMP-based PCR assays revealed a moderate agreement
as determined by the Kappa statistic (0.6 and 0.57, respec-
tively). Furthermore, the difference was not statistically
significant ( p = 0.79). However, the results showed that
the IDEIATM PCE test in comparison with PCR has lowerFigure 2 PCR amplification product for MOMP. Lane 1: mole-
cular weight ladder (100 bp); lane 2: positive control; lane 3:
negative control; lanes 4, 6, 7, 8: positive specimen PCR products
for MOMP (182 bp); lanes 9, 10: negative specimens.sensitivity (73%) and specificity (94%). The lower specificity
could be explained by the presence of false-positive results,
which could be attributed to some cross-reaction with other
infectious components such as Gram-negative bacterial LPS.
This explanation is supported by other recently conducted
studies, which have shown that EIA has low sensitivity and
specificity when compared to nucleic acid amplification
tests.23 In addition, the LPS-based EIA tests detect all three
chlamydial species and, therefore, are not species-specific.
The sensitivity of the plasmid-based PCR was 100% and
that for the MOMP-based PCR was 86%. A possible explanation
for discrepancies in the results of our study between the
plasmid- and MOMP-based PCRs might be a difference in the
target used for the amplification. The PCR assay that we used
to detect C. trachomatis is based on a cryptic plasmid primer,
which has been proved to be a more sensitive approach than
that used for the MOMP primer-based PCR,24 because plas-
mids are present in elementary bodies in multiple copies.
This may explain why five specimens were positive only by
plasmid-based PCR but not by the MOMP-based PCR.
In addition, the specificity of the plasmid-based PCR was
98% and that for the MOMP-based PCR was 100%. This dif-
ference could be explained by the presence of two false-
positive results in the plasmid-based PCR. Although these
were recorded as false-positive for analytical purposes, this
could also be explained by the slightly lower sensitivity of the
MOMP-based PCR, and also it is unlikely that C. trachomatis
infection would be excluded in such cases of symptomatic
patients. The remaining specimen, which was found positive
in both MOMP-based PCR and EIA, could contain a plasmid-
free variant of C. trachomatis. This is also supported by other
studies that have shown the possibility of encountering
plasmid-free strains.25,26
Univariate analysis showed that cervicitis, contact bleed-
ing, and infertility were significantly ( p < 0.05) associated
with chlamydial infection. Other symptomatic factors did not
reach statistical significance with chlamydial infection,
including low abdominal pain, low back pain, dysuria, dys-
pareunia, pruritis, and irregular menstruation. The age
groups 25—31 years and 32—38 years were those with the
340 I.A. El Qouqa et al.highest rate of infection. This finding is inconsistent with
those of other studies that have shown a decline in the
prevalence rate after 25 years of age.27,28 Furthermore,
women with an elementary education level showed the high-
est rate of chlamydial infection, while residency in a rural
area revealed higher infection than residency in an urban
area. However, in multivariate logistic regression analysis,
cervicitis was the only independent factor associated with
chlamydial infection.
Infertility is an emerging health problem in many coun-
tries of the world including Palestine. The increase appears
to coincide with the growing role played by C. trachomatis
as a sexually transmitted disease. In our study, C. tracho-
matis infection was found in 28.6% (14/49) of the infertile
women, which is quite high and surprising. This could be
attributed to previous infection with C. trachomatis. The
prevalence of C. trachomatis infection was more common
in women with secondary infertility. This finding has been
reported by other investigators.29 However, statistical ana-
lysis revealed no significant association with chlamydial
infection ( p = 0.13).
To the best of our knowledge, this is the first study from
Palestine that provides current data regarding the frequency
of genital C. trachomatis infection in married Palestinian
women suffering from gynecological problems and infertility,
and may be particularly helpful to physicians treating such
patients in Palestine, where the quality of women’s health-
care requires drastic improvement.
In conclusion, the prevalence of C. trachomatis in Gaza is
considerable. Women with cervicitis are more likely to have
been previously infected or exposed to chlamydial infection.
Furthermore, plasmid- and MOMP-based PCR assays are
superior and more efficient for the detection of C. tracho-
matis infection than EIA (IDEIATM PCE Chlamydia kit).
We recommend the introduction of a PCR technique as the
routine test for diagnosis of chlamydial infection in clinical
laboratories. Further studies on a larger sample size of the
general population are required, to more accurately deter-
mine the prevalence of C. trachomatis, to further identify
risk factors associated with chlamydial infection, and to
identify the prevalent C. trachomatis strains, which could
be useful for epidemiology and for the identification of both
mixed and re-infected patient cases.
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